|
Report: Cancer diagnostics market could hit $90 million by 2014
October 2010
SHARING OPTIONS:
NEW YORK—Cancer treatment is one area where the era of
personalized medicine is arriving, according to market research publisher
Kalorama Information. In its recent report, "The Worldwide
Market for Cancer
Diagnostics,"Kalorama predicts a $90 million market for pharmacodiagnostics,
tests that determine whether a treatment matches the
individual patient, by
2014.
According to the report, the information gleaned from the
Human Genome Project and
pharmacogenomics research by the drug industry is
making possible individualized drug therapy based on the genetic makeup of a
patient.
The concept has been talked about for some time, but Kalorama notes in
its biennial review of the cancer testing market that
with five U.S. Food and
Drug Administration (FDA)-approved test and
treatment products, including tests
for Herceptin, Gleevec, Erbitux and Tarceva, and with many others in
development, pharmacodiagnostics has moved
beyond the concept phase.
"Personalized medicine is not occurring overnight, but it is
occurring," says Shara
Rosen, lead diagnostic analyst for Kalorama Information.
"More and more physicians are using these tests, and more pharma companies are
getting
involved and looking to in vitro diagnostic (IVD) companies for
biomarker tools."
The report says that while
personalized medicine strategies
are not new—it's been eight years that Herceptin package inserts have labeled
tests for therapy-responsive patients—
the increase in drug and test development
points towards greater utilization of these products.
According to
Kalorama, histopathology IVD companies Dako,
Ventana Medical, Roche Diagnostics and Third Wave Technologies lead the market
with FDA-cleared tests.Oncotype DX was launched in the United States in 2004,
where it
has since been adopted as the standard of care for treating
early-stage breast cancer.Oncotype DX is recommended in the guidelines of the
American Society of Clinical Oncology (ASCO) and the National Comprehensive
Cancer Network (NCCN), and is extensively
reimbursed in the United States.
Physicians use Oncotype DX to predict the likelihood of chemotherapy benefit,
as
well as the likelihood of recurrence, for patients with early-stage breast
cancer, in order to make individualized treatment decisions about the addition
of chemotherapy to hormonal therapy.
By 2025, one in five new drugs could be labeled with a
companion test,
many of which will be cancer drugs, according to Kalorama. Many
of the new companion tests are being developed as diagnostic/prescription
partnerships.
There are scores of these cancer co-development projects
underway. Companies such as Qiagen/DxS, MolecularMD and Roche/454 Life Sciences
launched CE Marked test kits in 2008 and 2009. These tests are performed using
blood instead of biopsied tissue.
Kalorama believes better-than-average growth levels will
drive more companies
to this area.
"This trend to personalized medicine is expected to create a huge market
for cancer diagnostics in
combination with the commercialization of the
therapy," Rosen says. "We expect pharmacogenomics, predisposition diagnostics
and molecular diagnostics
to show 25 to 30 percent annual growth over the next
five to 10 years." Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|